ConductScience.org, home

Comparison · NCT03703310-c346437f

Patidegib Topical Gel, 2%, vs Patidegib Topical Gel, Vehicle: Percentage of Participants Developing >=2 Facial New BCCs

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Patidegib Topical Gel, 2%, vs Patidegib Topical Gel, Vehicle: Percentage of Participants Developing >=2 Facial New BCCs. Trial comparisons, record NCT03703310-c346437f. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03703310-c346437f

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.5420.4360.645wilson
Risk in group 20.640.5340.733wilson
Risk difference, group 1 minus group 2-0.0974-0.2390.05newcombe hybrid score
Risk ratio, group 1 over group 20.8480.6581.09log
Odds ratio, group 1 over group 20.6670.361.24log
Number needed to treat, for one fewer participant with the outcome on Patidegib Topical Gel, 2%, than on Patidegib Topical Gel, Vehicle10.3from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: vehicle.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Patidegib Topical Gel, 2%,
Participants will be randomized to receive Patidegib Topical Gel, 2%. The Patidegib Topical Gel, 2% will be dispensed to participants at each study visit and applied topically twice daily to the face.~Patidegib Topical Gel, 2%: Patidegib Topical Gel, 2%
4583OG000
Group 2Patidegib Topical Gel, Vehicle
Participants will be randomized to receive Vehicle. The Patidegib Topical Gel, Vehicle will be dispensed to participants at each study visit and applied topically twice daily to the face.~Patidegib Topical Gel, Vehicle: Patidegib Topical Gel, Vehicle
5586OG001

Outcome

Type
SECONDARY
Title
Percentage of Participants Developing >=2 Facial New BCCs
Description
Time frame
Month 12
Population
subjects with no postbaseline data were excluded from the analysis

Source ClinicalTrials.gov

Trial

Title
Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)
NCT number
NCT03703310
Phases
PHASE3
Conditions
Basal Cell Nevus Syndrome
Interventions
Patidegib Topical Gel, 2%, Patidegib Topical Gel, Vehicle
Lead sponsor
Sol-Gel Technologies, Ltd.
Results first posted
2024-07-03

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT03703310-c346437f